Danaher Management
Management Kriterienprüfungen 3/4
Danaher CEO ist Rainer Blair , ernannt in Sep 2020, hat eine Amtszeit von 5.67 Jahren. Die jährliche Gesamtvergütung beträgt $23.80M , bestehend aus 5.9% Gehalt und 94.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.01% der Aktien des Unternehmens, im Wert von $12.08M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 14.7 Jahre.
Wichtige Informationen
Rainer Blair
Geschäftsführender
US$23.8m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 5.88% |
| Amtszeit als Geschäftsführer | 5.7yrs |
| Eigentum des Geschäftsführers | 0.01% |
| Durchschnittliche Amtszeit des Managements | 2.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 14.7yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • May 19
DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple
Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.Narrativ-Update • May 02
DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple
Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.Seeking Alpha • Apr 22
Danaher Q1 2026 Earnings Update
Summary Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q’26. Life Sciences segment’s core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q’25. Management kept their core revenue guidance of ~3-6% but raised the high end of 2026 EPS guidance from $8.5 to $8.55. Read the full article on Seeking Alpha
Neues Narrativ • Apr 20
Danaher Corporation (DHR): The Life Sciences Titan and the "Diagnostic Diversification" Shift
Danaher Corporation (DHR) , the global life sciences and diagnostics innovator, enters Tuesday, April 21, 2026 , following a mixed but resilient first-quarter earnings performance. Trading at $195.60 USD —a marginal 0.05% gain in a volatile post-earnings session—the stock is seeking firm support above its recent low of $181.01.Narrativ-Update • Apr 16
DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple
Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.Narrativ-Update • Apr 01
DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple
Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.Narrativ-Update • Mar 18
DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple
Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.Narrativ-Update • Mar 04
DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple
The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.Narrativ-Update • Feb 17
DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple
Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.Narrativ-Update • Feb 03
DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook
Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.Narrativ-Update • Jan 19
DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple
Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.Narrativ-Update • Jan 05
DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple
Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.Narrativ-Update • Dec 19
DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers
Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.Narrativ-Update • Dec 04
DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty
Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.Narrativ-Update • Nov 20
DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside
Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.Narrativ-Update • Nov 04
DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds
Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.Narrativ-Update • Oct 21
Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher
Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.Narrativ-Update • Sep 11
Advanced Diagnostics And Personalized Therapies Will Expand Global Markets
Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.Analyseartikel • Aug 01
Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings
Danaher Corporation's ( NYSE:DHR ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...Analyseartikel • Jul 12
Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?
Key Insights Danaher's estimated fair value is US$304 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Mar 31
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Mar 22
Danaher: Near 5-Year Low Is A Great Entry Point
Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Danaher: Self-Inflicted Pessimism?
Summary Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company’s strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher’s bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment. Valuation analysis indicates the stock is currently undervalued, with potential for significant upside as market conditions improve and growth returns, making it a buy. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued
Summary Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles, Danaher has strong growth potential driven by secular tailwinds like an aging population and technological advancements in diagnostics. The company exhibits a wide economic moat due to high switching costs and stable margins, but its RoIC is below the ideal threshold. Currently, Danaher is overvalued with high P/E and P/FCF ratios, making it a "Hold" rather than a buy, pending future performance improvements. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Summary Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors. Trading at a reasonable valuation, Danaher is poised for a rebound with expected double-digit EPS growth, making it an excellent choice for long-term accumulation. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Danaher: A Resilient And Solid Company With Growth Potential
Summary Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales. The company has been successful in generating growth through acquiring other companies. In the last ten years, half of Danaher's growth has come due to this strategy. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Understanding Danaher's Cautiousness
Summary Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 27 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$24m | US$1m | US$4b |
| Sep 26 2025 | n/a | n/a | US$4b |
| Jun 27 2025 | n/a | n/a | US$3b |
| Mar 28 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$22m | US$1m | US$4b |
| Sep 27 2024 | n/a | n/a | US$4b |
| Jun 28 2024 | n/a | n/a | US$4b |
| Mar 29 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$1m | US$4b |
| Sep 29 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$20m | US$1m | US$6b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jul 01 2022 | n/a | n/a | US$6b |
| Apr 01 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$17m | US$1m | US$5b |
| Oct 01 2021 | n/a | n/a | US$6b |
| Jul 02 2021 | n/a | n/a | US$5b |
| Apr 02 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$10m | US$949k | US$4b |
| Oct 02 2020 | n/a | n/a | US$3b |
| Jul 03 2020 | n/a | n/a | US$3b |
| Apr 03 2020 | n/a | n/a | US$3b |
| Dec 31 2019 | US$7m | US$840k | US$2b |
Vergütung im Vergleich zum Markt: RainerDie Gesamtvergütung ($USD23.80M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.79M).
Entschädigung vs. Einkommen: RainerDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Rainer Blair (61 yo)
5.7yrs
Amtszeit
US$23,795,280
Vergütung
Mr. Rainer M. Blair serves as an Independent Non-Executive Director at Nestlé S.A. since April 20, 2023. He serves as President, Chief Executive Officer and Director at Danaher Corporation since September...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder & Chairman | 43.3yrs | keine Daten | 5.97% $ 7.3b | |
| President | 5.7yrs | US$23.80m | 0.0099% $ 12.1m | |
| Co-Founder & Director | 43.3yrs | keine Daten | 4.77% $ 5.8b | |
| Senior VP & Chief Science Officer | 5.4yrs | US$6.24m | 0.0011% $ 1.4m | |
| Executive Vice President | less than a year | US$7.97m | 0.0040% $ 4.9m | |
| Executive VP of Biotechnology Group & CEO of Cytiva | 2.3yrs | US$11.26m | 0.00059% $ 718.2k | |
| Executive Vice President of Diagnostics Platform | 1.8yrs | US$11.30m | 0.00080% $ 973.9k | |
| Executive VP & CFO | less than a year | keine Daten | 0.0011% $ 1.3m | |
| VP & Chief Accounting Officer | 4.3yrs | keine Daten | 0.00098% $ 1.2m | |
| Chief Technology & AI Officer | less than a year | keine Daten | keine Daten | |
| Vice President of Investor Relations | no data | keine Daten | keine Daten | |
| Senior VP & Chief Legal Officer | less than a year | keine Daten | keine Daten |
2.3yrs
Durchschnittliche Betriebszugehörigkeit
53yo
Durchschnittliches Alter
Erfahrenes Management: DHRDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder & Chairman | 43.3yrs | keine Daten | 5.97% $ 7.3b | |
| President | 5.7yrs | US$23.80m | 0.0099% $ 12.1m | |
| Co-Founder & Director | 43.3yrs | keine Daten | 4.77% $ 5.8b | |
| Independent Director | 27.3yrs | US$351.03k | 0.012% $ 14.9m | |
| Independent Director | 17.3yrs | US$373.53k | 0.0023% $ 2.8m | |
| Independent Director | 9.3yrs | US$351.03k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 5.1yrs | keine Daten | keine Daten | |
| Lead Independent Director | 20.4yrs | US$413.53k | 0.0031% $ 3.7m | |
| Member of Scientific Advisory Board | 5.1yrs | keine Daten | keine Daten | |
| Independent Director | 14.7yrs | US$379.53k | 0% $ 0 | |
| Independent Director | 5yrs | US$378.53k | 0% $ 0 |
14.7yrs
Durchschnittliche Betriebszugehörigkeit
63yo
Durchschnittliches Alter
Erfahrener Vorstand: DHRDie Vorstandsmitglieder sind sehr erfahren ( 14.7 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/25 12:36 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/27 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Danaher Corporation wird von 44 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |